A Pharmacovigilance Study on Clozapine in the Food and Drug Administration Adverse Event Reporting System: A Regional Comparative Analysis

키워드

참고문헌 (33)

1. Barnes TR, "Evidence-based guidelines for the pharmacological treatment of schizophrenia : updated recommendations from the British Association for Psychopharmacology", J Psychopharmacol, 34, pp.3~78 (2020)
2. Galletly C, "Royal Australian and New Zealand College of Psychiatrists clinical practice guidelines for the management of schizophrenia and related disorders", Aust N Z J Psychiatry, 50, pp.410~472 (2016)
3. Keepers GA, "The American Psychiatric Association practice guideline for the treatment of patients with schizophrenia", Am J Psychiatry, 177, pp.868~872 (2020)
4. Huhn M, "Comparative efficacy and tolerability of 32 oral antipsychotics for the acute treatment of adults with multi-episode schizophrenia : a systematic review and network meta-analysis", Lancet, 394, pp.939~951 (2019)
5. Masuda T, "Association with hospitalization and all-cause discontinuation among patients with schizophrenia on clozapine vs other oral second-generation antipsychotics : a systematic review and meta-analysis of cohort studies", JAMA Psychiatry, 76, pp.1052~1062 (2019)
6. Bachmann CJ, "International trends in clozapine use : a study in 17 countries", Acta Psychiatr Scand, 136, pp.37~51 (2017)
7. Xu SW, "Clozapine prescription pattern in patients with schizophrenia in Asia : the REAP survey(2016)", Psychiatry Res, 287, pp.112271~ (2020)
8. Moore TJ, "Serious adverse drug events reported to the Food and Drug Administration, 1998-2005", Arch Intern Med, 167, pp.1752~1759 (2007)
9. Wiciński M, "Clozapine-induced agranulocytosis", granulocytopenia : mechanisms and monitoring, 2018, pp.25, 22~28
10. Ronaldson KJ, "A new monitoring protocol for clozapine-induced myocarditis based on an analysis of 75 cases and 94 controls", Aust N Z J Psychiatry, 45, pp.458~465 (2011)
11. de Leon J, "An international adult guideline for making clozapine titration safer by using six ancestry-based personalized dosing titrations, CRP, and clozapine levels", Pharmacopsychiatry, 55, pp.73~86 (2022)
12. De Leon J, "Data from the World Health Organization's pharmacovigilance database supports the prominent role of pneumonia in mortality associated with clozapine adverse drug reactions", Schizophr Bull, 46, pp.1~3 (2020)
13. Kumlien E, "Seizure risk associated with neuroactive drugs : data from the WHO adverse drug reactions database", Seizure, 19, pp.69~73 (2010)
14. Lertxundi U, "Antipsychotics and seizures : higher risk with atypicals?", Seizure, 22, pp.141~143 (2013)
15. Schoretsanitis G, "Blood levels to optimize antipsychotic treatment in clinical practice : a joint consensus statement of the American Society of Clinical Psychopharmacology and the Therapeutic Drug Monitoring Task Force of the Arbeitsgemeinschaft für Neuropsychopharmakologie und Pharmakopsychiatrie", J Clin Psychiatry, 81, pp.19~ (2020)
16. Polcwiartek C, "The clinical potentials of adjunctive fluvoxamine to clozapine treatment : a systematic review", Psychopharmacology(Berl), 233, pp.741~750 (2016)
17. de Leon J, "Do Asian patients require only half of the clozapine dose prescribed for Caucasians? A critical overview", Indian J Psychol Med, 42, pp.4~10 (2020)
18. Ruan CJ, "Clozapine metabolism in East Asians and Caucasians : a pilot exploration of the prevalence of poor metabolizers and a systematic review", J Clin Psychopharmacol, 39, pp.135~144 (2019)
19. Singh R, ""Asian"phenotype underestimates the genetic diversity of asia yet overstates its impact on variability in drug disposition and pharmacodynamics", Clin Pharmacol Ther, 105, pp.802~805 (2019)
20. "Medical Dictionary for Regulatory Activities/Japanese version (MedDRA/J) version 25.0" (2022)[URL]
21. Yasui-Furukori N, "Japanese patients need slower, personalized clozapine titrations : a comment on the case described by Kikuchi et al", PCN Rep, 2, pp.e70~ (2023)
22. Kikuchi Y, "Slower clozapine titration than the official Japanese protocol led to fewer inflammatory adverse effects: a retrospective chart review of seven hospitals", Schizophr Res (2023)[DOI]
23. Kang N, "Association between initial pattern of clozapine titration, concentration-to-dose ratio, and incidence of fever in patients with schizophrenia spectrum disorders in a Korean tertiary hospital", Schizophr Res (2023)[DOI]
24. Kang N, "Association between initial clozapine titration and pneumonia risk among patients with schizophrenia in a Korean tertiary hospital", Schizophr Res (2023)[DOI]
25. Gallego JA, "Safety and tolerability of antipsychotic polypharmacy", Expert Opin Drug Saf, 11, pp.527~542 (2012)
26. Hatano M, "Analysis of clozapine-induced seizures using the Japanese Adverse Drug Event Report database", PLoS One, 18, pp.e0287122~ (2023)
27. Lee JW, "Trends in the prevalence of type 2 diabetes in Asians versus whites : results from the United States National Health Interview Survey, 1997-2008", Diabetes Care, 34, pp.353~357 (2011)
28. De Las Cuevas C, "Clozapine-associated myocarditis in the World Health Organization's pharmacovigilance database : focus on reports from various countries", Rev Psiquiatr Salud Ment(Engl Ed), 15, pp.238~250 (2022)
29. Winckel K, "Clozapine-induced myocarditis : separating the wheat from the chaff", Aust N Z J Psychiatry, 49, pp.188~ (2015)
30. Wagner E, "Impact of smoking behavior on clozapine blood levels-a systematic review and meta-analysis", Acta Psychiatr Scand, 142, pp.456~466 (2020)
31. Hägg S, "Effect of caffeine on clozapine pharmacokinetics in healthy volunteers", Br J Clin Pharmacol, 49, pp.59~63 (2000)
32. Noguchi Y, "Detection algorithms and attentive points of safety signal using spontaneous reporting systems as a clinical data source", Brief Bioinform, 22, pp.bbab347~ (2021)
33. De Las Cuevas C, "Adverse drug reactions and their fatal outcomes in clozapine patients in VigiBase:comparing the top four reporting countries (US, UK, Canada and Australia)", Schizophr Res (2023)[DOI]

관련 논문AI추천